H.C. Wainwright initiated coverage of Nyxoah with a Buy rating and $15 price target. Nyxoah is a medtech company with an innovative treatment for obstructive sleep apnea, the analyst tells investors in a research note. The firm believes U.S. approval of the Genio system would be a substantial catalyst that could drive the stock price higher.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NYXH:
- Nyxoah to Participate in the 43rd Canaccord Genuity Growth Conference
- Nyxoah to Release Second Quarter 2023 Financial Results on August 8, 2023
- Information on the Total Number of Voting Rights and Shares
- Publication Relating to a Transparency Notification
- Nyxoah initiated with Neutral on U.S. ‘hurdles’ at Baird
